BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35365044)

  • 1. Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review.
    Jiang Y; Zhang L; Zhu F; Zhu H; Cao X; Zhang Y
    Ann Palliat Med; 2022 Mar; 11(3):1135-1146. PubMed ID: 35365044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
    Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
    Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.
    Deng W; Chen J; Deng XY
    Front Immunol; 2024; 15():1333850. PubMed ID: 38487532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.
    Wu Y; Zhang T; Liu Y; Wang J; Bi N
    Ann Palliat Med; 2021 Feb; 10(2):2379-2386. PubMed ID: 33725780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surufatinib combined camrelizumab as a valuable third-line rescue therapy for a patient with extensive-stage for small-cell lung cancer: a case report and literature review.
    Pan C; Yu T; Han L; Hao D; Yang M; Li L; Chu L; Ni Q
    Anticancer Drugs; 2024 Mar; 35(3):271-276. PubMed ID: 37948349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
    Yu G; Cai Q; Xu X; Shen Y; Xu K
    PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
    Wu G; Huang J; Lin L; Yan S; Pan W; Chen Q; Wu X; Lv D
    Immunotherapy; 2022 Sep; 14(13):1007-1013. PubMed ID: 35852100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.
    Zhou N; Jiang M; Li T; Zhu J; Liu K; Hou H; Zhang X
    Lung Cancer; 2021 Oct; 160():111-117. PubMed ID: 34482102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
    Su H; Yu C; Ma X; Song Q
    Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
    Chiang AC; Sequist LVD; Gilbert J; Conkling P; Thompson D; Marcoux JP; Gettinger S; Kowanetz M; Molinero L; O'Hear C; Fassò M; Lam S; Gordon MS
    Clin Lung Cancer; 2020 Sep; 21(5):455-463.e4. PubMed ID: 32586767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report.
    Sun C; Ma X; Jiang L; Zhu X
    Anticancer Drugs; 2024 Apr; 35(4):358-361. PubMed ID: 38385998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
    Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
    Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.
    Gao F; Cong X; Liu Z
    Medicine (Baltimore); 2020 Oct; 99(40):e22637. PubMed ID: 33019486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
    Ott PA; Elez E; Hiret S; Kim DW; Morosky A; Saraf S; Piperdi B; Mehnert JM
    J Clin Oncol; 2017 Dec; 35(34):3823-3829. PubMed ID: 28813164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.
    Fan Y; Zhao J; Wang Q; Huang D; Li X; Chen J; Fang Y; Duan J; Zhou C; Hu Y; Yang H; Hu Y; Zhou J; Lin X; Wang L; Wang Z; Xu Y; Zhang T; Shi W; Zou J; Wang J
    J Thorac Oncol; 2021 Feb; 16(2):299-309. PubMed ID: 33166719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.